Variable Variable Outcomes Outcomes Crude OR
(95%CI)
Adjusted OR
(95%CI)
Non-death
n (%)
Death
n (%)
Sex Female 846 (80.0) 211 (20.0) ref. ref.
Male 362 (73.4) 131 (26.6) 1.45
(1.13–1.86)
1.50
(1.15–1.94)
Age <60 677 (85.8) 112 (14.2) ref. ref.
≥60 531 (69.8) 230 (30.2) 2.62
(2.04–3.38)
2.44
(1.87–3.21)
Epoprostenol Non-use 931 (75.9) 296 (24.1) ref. ref.
User 277 (85.8) 46 (14.2) 0.52
(0.37–0.73)
0.66
(0.44–0.98)
Sildenafil Non-use 971 (79.9) 245 (20.1) ref. ref.
User 237 (71.0) 97 (29.0) 1.62
(1.23–2.13)
1.50
(1.08–2.07)
Tadalafil Non-use 726 (76.0) 229 (24.0) ref. ref.
User 482 (81.0) 113 (19.0) 0.74
(0.58–0.96)
0.85
(0.63–1.15)
Riociguat Non-use 1116 (77.4) 325 (22.6) ref. ref.
User 92 (84.4) 17 (15.6) 0.63
(0.36–1.05)
0.64
(0.35–1.10)
Oxygen Non-use 1004 (76.9) 301 (23.1) ref. ref.
User 204 (83.3) 41 (16.7) 0.67
(0.46–0.95)
0.63
(0.43–0.90)
Warfarin Non-use 957 (77.2) 283 (22.8) ref. ref.
User 251 (81.0) 59 (19.0) 0.79
(0.58–1.08)
0.67
(0.47–0.95)
Epoprostenol:Warfarin
(Interaction term)
Epoprostenol:Warfarin
(Interaction term)
- - - 1.87
(0.76–4.32)
OR, odds ratio; CI, confidence interval; ref., reference OR, odds ratio; CI, confidence interval; ref., reference OR, odds ratio; CI, confidence interval; ref., reference OR, odds ratio; CI, confidence interval; ref., reference OR, odds ratio; CI, confidence interval; ref., reference OR, odds ratio; CI, confidence interval; ref., reference